Medical data and services provider LinkDoc Technology has raised an undisclosed amount from Alibaba’s healthcare arm Alihealth, per a company statement on Thursday.
This marks a strategic investment in the company.
LinkDoc and Alihealth will work together to improve their oncology-driven internet service platform.
Last year, in October, LinkDoc raised 700 million yuan ($108 million) in its Series D+ round from CICC, Youshan Capital and CBC Capital’s funds of funds iFOF.
LinkDoc delivers structured data and AI solutions for oncology and rare diseases through smart data platform. It offers a gamut of services including medicine distribution, healthcare data management, online doctor management, and scientific research, among others.
Before this, LinkDoc has closed three other rounds of funding from CBC Capital, state-owned China Investment Corporation, Cenova Ventures, Hong Kong-based Ally Bridge Group and US-based New Enterprise Associates.
CHINA DEAL MONITOR
DealStreetAsia has also put together a table listing out all prominent venture capital transactions in the Greater China region on March 3-4, 2021.
|Startup||Headquarter||Investment Size (USD)||Investment Stage||Lead Investor(s)||Other Investor(s)||Verticals|
|SVOLT Energy Technology||Wuxi||541 million||A||Bank of China, CMG-SDIC Fund Management||Beijing Financial Street Capital Operation Center, Guangzhou Venture Capital Group, ZJU Jiuzhi Investment Management, IDG Capital, Cathay Capital, HT Capital||Electric/Hybrid Vechicles|
|ECARX||Hangzhou||200 million||A+||State-owned China Venture Capital Fund||-||AI and Machine Learning|
|Cygnus Semi||Shanghai||62 million||Pre-IPO||VGC||GL Ventures, Fosun, GGV Capital, GP Capital, Shanghai Puluo Equity Investment Management, Vision Knight Capital, Green Pine Capital Partners, Wofu Capital||Internet of Things|
|moody||Shanghai||59 million||B, B+||B: GGV Capital, B+: CPE||B: XVC, GL Ventures, Matrix Partners China, Source Code Capital, B+: GGV Capital, XVC, GL Ventures, Matrix Partners China, Source Code Capital||N/A|
|Bluepha||Beijing||30 million||B||Hillhouse Capital, Lightspeed China Partners||Septwolves Ventures, Trinity Innovation Fund, Frees Fund, Qianhai FOF, ZGC Group's Qihang fund and development fund||Biotech|
|New Vision Electronics||Yizheng||23 million||C||Capitalink||Before Capital, Xinding Capital, YTHY, Cogent Capital||AI and Machine Learning|
|NOLO VR||Beijing||20 million||B||NIO Capital||Bluerun Ventures, Joy Capital||AR & VR|
|Calibra||Hangzhou||* 15 million||B||B: GL Ventures||A: BioTrack Capital, B: GL Capital, Green Pine Capital Partners||HealthTech|
|Litecore||Fuzhou||* 15 million||-||Legend Capital||-||N/A|
|Rebo||Chongqing||15 million||Pre-IPO||V Fund||Redhorse Capital||N/A|
|Gencells Therapeutics||Shanghai||15 million||A||Kaitai Capital||Shanghai Fu Rong Investment||N/A|
|Shanghai Mathartsys Software||Shanghai||15 million||-||-||SIG Capital||Big Data|
|yo-i.com||Shanghai||15 million||Strategic Investment||Tencent Cloud, Langcheng Capital||Changshu Dongnan Industry Fund||Internet of Things|
|Pharmacin||Shenzhen||15 million||B1||-||Kaitai Capital||HealthTech|
|Lingcai Technology||Beijing||* 1.5 million||A||Matrix Partners China||Fengyang Capital||Fintech|
|Moore Threads||Beijing||-||Pre-A||Shenzhen Capital,GGV Capital, Sequoia Capital China||China Merchants Capital, ByteDance, Pony.ai, Riverhead Capital, Oceanpine Capital, Wenming Investment, First Capital, 5Y Capital, HeT, Minghao Investment||AI and Machine Learning|
∗ indicates that the company did not provide the specific size of the deal but only a range. So, we adopted the smallest number in the range, which is “7 million yuan ($1 million)” in the given example.